Charlene W. Compher BS, MS, PhD, RD, CNSC, LDN, FAND, FASPEN

Dr. Compher’s clinical work has been the inspiration for her research, including several clinical trials that contributed to the 2012 FDA approval of teduglutide, the first targeted therapy for short bowel syndrome to reduce intravenous nutrition for these patients. More recently, Dr. Compher and colleagues compared the effectiveness of exclusive enteral nutrition feeding, partial enteral nutrition, and biological therapy on Crohn’s disease in children. They found that exclusive enteral nutrition and biological therapy had similar effectiveness. Another study of critically ill patients found that higher protein intake was associated with improved survival and faster discharge.